SunLink Health Systems, Inc. (NYSE American: SSY) today
announced earnings from continuing operations of $2,052,000 ($0.29
per fully diluted share) for its second fiscal quarter ended
December 31, 2022 compared to a loss from continuing operations of
$477,000 (or a loss of $0.07 per fully diluted share) for the
second fiscal quarter ended December 31, 2021. Net earnings for the
quarter ended December 31, 2022 were $1,951,000 ($0.28 per fully
diluted share) compared to a net loss of $593,000 (or a loss of
$0.09 per fully diluted share) for the quarter ended December 31,
2021.
The fiscal quarter ended December 31, 2022, included recognition
of net revenues of $2,615,000 from the reversal of reserves for
certain sales taxes previously accrued by the Pharmacy Segment. The
company determined during the quarter that, based upon discussions
with and correspondence from taxing authorities and consultation
with external legal counsel, it was more likely than not that such
accrued sales taxes will not be payable.
The fiscal quarter ended December 31, 2021 included Provider
Relief Funds (“PRF”) of $614,000 (pre-tax).
Consolidated net revenues for the quarters ended December 31,
2022 and 2021 were $14,392,000 and $10,411,000, respectively, an
increase of 38.2% in the current year’s quarter compared to the
comparable quarter of the prior fiscal year. Healthcare Services
Segment net revenues increased 18.1% from the comparable fiscal
quarter of the prior year due to increased hospital admissions and
increased nursing home admissions this current quarter and Pharmacy
Segment net revenues increased 47.7% from the comparable fiscal
quarter of the prior fiscal year due to the recognition of income
from the reversal of reserves for certain sales taxes previously
accrued and increased retail and institutional pharmacy and Durable
Medical Equipment (“DME”) sales in the fiscal quarter ended
December 31, 2022.
SunLink reported operating profit for the quarter ended December
31, 2022 of $2,040,000 compared to an operating loss for the
quarter ended December 31, 2021 of $1,072,000. The substantial
increase in operating profit from last year’s comparable quarter
was due to the previously mentioned recognition of income from
reversal of the reserves for certain sales taxes previously accrued
of $2,615,000. Excluding this adjustment, the resulting operating
loss in the current year’s quarter would have been less than last
year due to higher net revenues and slightly lower wages and
benefits expense.
Loss from discontinued operations was $101,000 (or a loss of
$0.01 per fully diluted share) for the quarter ended December 31,
2022 compared to a loss from discontinued operations of $116,000
(or $0.02 per fully diluted share) for the quarter ended December
31, 2021.
Earnings from continuing operations for the six months ended
December 31, 2022 were $508,000 ($0.07 per fully diluted share)
compared to earnings from continuing operations for the six months
ended December 31, 2021 of $1,529,000 ($0.22 per fully diluted
share). Net earnings for the six months ended December 31, 2022
were $393,000 ($0.06 per fully diluted share) compared to net
earnings of $1,346,000 ($0.19 per fully diluted share) for the six
months ended December 31, 2021.
The six months ended December 31, 2022 included recognition of
income from reversal of certain sales taxes previously accrued by
its Pharmacy Segment which resulted in a $2,615,000 increase to net
revenues, as well as PRF of $61,000 (pre-tax). The six months ended
December 31, 2021 included forgiveness of Paycheck Protection Plan
(“PPP”) loans of $3,010,000 (pre-tax) and PRF of $614,000
(pre-tax).
Consolidated net revenues for the six months ended December 31,
2022 and 2021 were $25,429,000 and $20,936,000, respectively, an
increase of 21.5% in the current year’s quarter compared to the
comparable quarter of the prior fiscal year. Healthcare Services
Segment net revenues increased 13.0% from the prior year due to
increased hospital admissions, clinic visits and increased nursing
home admissions this year, and the Pharmacy Segment net revenues
increased 25.5% from the prior year due to the recognition of
income from reversal of reserves for certain sales taxes previously
accrued and increased retail and institutional pharmacy sales this
year.
SunLink reported operating profit for the six months ended
December 31, 2022 of $427,000 compared to an operating loss for the
six months ended December 31, 2021 of $2,065,000. The operating
profit from this year was due to the previously mentioned
recognition of income from the reversal of reserves for certain
sales taxes previously accrued of $2,615,000 in this year’s second
fiscal quarter.
Loss from discontinued operations was $115,000 (or a loss of
$0.02 per fully diluted share) for the six months ended December
31, 2022 compared to a loss from discontinued operations of
$183,000 (or $0.03 per fully diluted share) for the six months
ended December 31, 2021.
The company’s cash and cash equivalents on December 31, 2022 was
$5,156,000, a decline of $1,638,000 from June 30, 2022, due to the
six month’s operating loss and capital expenditures by both the
Healthcare Service and Pharmacy Segments.
COVID-19 Pandemic
The Company continued to experience adverse effects of the
COVID-19 pandemic and its aftermath of the COVID-19 pandemic for
the last quarter and believes it will continue to affect its assets
and operations in the foreseeable future. Our ability to make
estimates of any continuing effect of the COVID-19 pandemic and its
aftermath on revenues, expenses or changes in accounting judgments
that have had or are reasonably likely to have a material effect on
our financial statements is currently limited. The nature and
extent of the continuing effect of the COVID-19 pandemic and its
aftermath on our balance sheet and results of operations will
depend on the severity and length of the evolving strains of
COVID-19; any further government actions and/or regulatory changes
to address the continuing effect of the pandemic; especially those
that affect our hospital, extended care, rehabilitation center,
nursing home, clinics, and our pharmacy operations; existing and
potential government assistance that may be provided; and the
requirements of PRF, including our ability to retain such PRF
received.
SunLink Health Systems, Inc. is the parent company of
subsidiaries that own and operate healthcare properties and
businesses in the Southeast. Each of the Company’s businesses is
operated locally with a strategy of linking patients’ needs with
healthcare professionals. For additional information on SunLink
Health Systems, Inc., please visit the Company’s website.
This press release contains certain forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995 including, without limitation, statements regarding the
company’s business strategy. These forward-looking statements are
subject to certain risks, uncertainties, and other factors, which
could cause actual results, performance, and achievements to differ
materially from those anticipated. Certain of those risks,
uncertainties and other factors are disclosed in more detail in the
company’s Annual Report on Form 10-K for the year ended June 30,
2022 and other filings with the Securities and Exchange Commission
which can be located at www.sec.gov.
SUNLINK HEALTH SYSTEMS, INC.
ANNOUNCES
FISCAL 2023 SECOND QUARTER RESULTS Amounts in 000's,
except per share CONSOLIDATED STATEMENTS OF EARNINGS
(LOSS)
Three Months Ended December
31,
Six Months Ended December
31,
2022
2021
2022
2021
% of Net
% of Net
% of Net
% of Net
Amount
Revenues
Amount
Revenues
Amount
Revenues
Amount
Revenues
Net Revenues
$
14,392
100.0
%
$
10,411
100.0
%
$
25,429
100.0
%
$
20,936
100.0
%
Costs and Expenses: Cost of goods sold
4,518
31.4
%
4,016
38.6
%
8,887
34.9
%
8,089
38.6
%
Salaries, wages and benefits
4,667
32.4
%
4,789
46.0
%
9,997
39.3
%
9,487
45.3
%
Supplies
401
2.8
%
308
3.0
%
738
2.9
%
608
2.9
%
Purchased services
999
6.9
%
783
7.5
%
2,034
8.0
%
1,645
7.9
%
Other operating expenses
1,254
8.7
%
1,101
10.6
%
2,347
9.2
%
2,183
10.4
%
Rents and leases
126
0.9
%
120
1.2
%
244
1.0
%
290
1.4
%
Depreciation and amortization
387
2.7
%
366
3.5
%
755
3.0
%
699
3.3
%
Operating profit (loss)
2,040
14.2
%
(1,072
)
-10.3
%
427
1.7
%
(2,065
)
-9.9
%
Interest Income (expense) - net
9
0.1
%
(3
)
0.0
%
5
0.0
%
(17
)
-0.1
%
Forgiveness of PPP loans and accrued interest
0
0.0
%
0
0.0
%
0
0.0
%
3,010
14.4
%
Federal pandemic stimulus- provider relief funds
0
0.0
%
614
5.9
%
61
0.2
%
614
2.9
%
Gain on sale of assets
2
0.0
%
7
0.1
%
14
0.1
%
12
0.1
%
Earnings (Loss) from Continuing Operations before Income
Taxes
2,051
14.3
%
(454
)
-4.4
%
507
2.0
%
1,554
7.4
%
Income Tax (benefit) expense
(1
)
0.0
%
23
0.2
%
(1
)
0.0
%
25
0.1
%
Earnings (Loss) from Continuing Operations
2,052
14.3
%
(477
)
-4.6
%
508
2.0
%
1,529
7.3
%
Loss from Discontinued Operations, net of tax
(101
)
-0.7
%
(116
)
-1.1
%
(115
)
-0.5
%
(183
)
-0.9
%
Net Earnings (Loss)
$
1,951
13.6
%
$
(593
)
-5.7
%
$
393
1.5
%
$
1,346
6.4
%
Earnings (Loss) Per Share from Continuing Operations: Basic
$
0.29
$
(0.07
)
$
0.07
$
0.22
Diluted
$
0.29
$
(0.07
)
$
0.07
$
0.22
Earnings (Loss) Per Share from Discontinued Operations: Basic
$
(0.01
)
$
(0.02
)
$
(0.02
)
$
(0.03
)
Diluted
$
(0.01
)
$
(0.02
)
$
(0.02
)
$
(0.03
)
Net Earnings (Loss) Per Share: Basic
$
0.28
$
(0.09
)
$
0.06
$
0.19
Diluted
$
0.28
$
(0.09
)
$
0.06
$
0.19
Weighted Average Common Shares Outstanding: Basic
7,031
6,947
7,007
6,935
Diluted
7,033
6,947
7,010
7,099
SUMMARY BALANCE SHEETS
December 31,
June 30,
2022
2022
ASSETS Cash and Cash Equivalents
$
5,156
$
6,794
Receivable - net
4,475
4,624
Other Current Assets
5,393
5,397
Property Plant and Equipment, net
8,427
8,217
Long-term Assets
2,718
2,911
$
26,169
$
27,943
LIABILITIES AND SHAREHOLDERS' EQUITY Current Liabilities
$
5,633
$
7,691
Long-term Debt and Other Noncurrent Liabilities
975
1,132
Shareholders' Equity
19,561
19,120
$
26,169
$
27,943
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230215005661/en/
Robert M. Thornton, Jr. Chief Executive Officer
(770) 933-7004
Sunlink Health Systems (AMEX:SSY)
Historical Stock Chart
From May 2024 to Jun 2024
Sunlink Health Systems (AMEX:SSY)
Historical Stock Chart
From Jun 2023 to Jun 2024